Purpose To analyze and summarize the efficacy of immune checkpoint inhibitor (ICI) alone
or in combination therapy for renal cell carcinoma (RCC) and urothelial carcinoma (UC) …

Aim: To compare the efficacy of first-line immune checkpoint inhibitor (ICI)-based
combinations in metastatic renal cell carcinoma (mRCC) patients stratified by chronological …

Context Advances in systemic agents have increased overall survival for men diagnosed
with metastatic prostate cancer. Additional cytoreductive prostate treatments and metastasis …

Methods EmBASE and Medline databases were accessed to identify all relevant articles
focused on mCNPC or mCSPC published between January 2000 and April 2022 with the …

Immune checkpoint inhibitor (ICI)-based combination therapies are the recommended first-
line treatment for metastatic renal cell carcinoma (mRCC). However, no head-to-head phase …

Aim: This study reports the outcomes of cytoreductive prostate cryoablation and metronomic
cyclophosphamide for the treatment of metastatic hormone-sensitive prostate cancer …

Objective To evaluate the efficacy of systemic therapies in patients with worse performance
status (PS) treated for high‐risk non‐metastatic prostate cancer (PCa), metastatic hormone …

Background and objective Cytoreductive treatments for patients diagnosed with de novo
synchronous metastatic hormone-sensitive prostate cancer (mHSPC) confer incremental …

Abstract Purpose of Review Metastatic prostate cancer remains universally lethal. Although
de-novo metastatic prostate cancer was historically managed with systemic therapy alone …

Prostate cancer (PCa) is the second most common malignancy in men, but its exact
pathogenetic mechanisms remain unclear. This study explores the effect of enhancer RNAs …